![]() |
市場調查報告書
商品編碼
1309703
胰島素泵全球市場規模/份額/行業趨勢分析報告:產品、適應症、分銷渠道(零售店/在線藥房、醫院藥房)、地區的展望和預測,2023-2030Global Insulin Pump Market Size, Share & Industry Trends Analysis Report By Product, By Disease Indication, By Distribution Channel (Retail & Online Pharmacies, and Hospital Pharmacy), By Regional Outlook and Forecast, 2023 - 2030 |
到 2030 年,胰島素泵市場預計將達到 95 億美元,預測期內復合年增長率為 9.9%。
根據 KBV 基數矩陣中的分析,F. Hoffmann-La Roche Ltd. 是市場領導者。 2021 年 1 月,F. Hoffmann-La Roche 與 Montmed Inc. 建立合作夥伴關係,為加拿大客戶提供 SiteSmart 筆針系統。 此次合作支持羅氏改善糖尿病管理的目標。 Medtronic PLC、Aetna, Inc. 和 Insulet Corporation 等公司是該市場的主要創新者。
新冠肺炎 (COVID-19) 的影響
COVID-19的爆發阻礙了胰島素泵市場的擴張。 糖尿病診斷和治療的延遲以及患者購買泵的延遲是促成因素。 此外,在 COVID-19 大流行期間,多個政府制定了法規,中斷了泵和消耗品的供應。 例如,美國糖尿病協會報告稱,在大流行期間,15% 使用泵或 CGM 的糖尿病患者延遲了補充供應。 由於對該疾病的認識和診斷的提高,預計 2021 年 CGM 和閉環泵的銷量將增長 20%。 2020年市場參與者的收入利潤率大幅下降。
市場增長因素
全球糖尿病患病率上升
糖尿病在發達國家和新興國家都變得越來越普遍。 這是多種因素造成的,包括肥胖和久坐的生活方式。 糖尿病事實和數據表明糖尿病對世界各地的人們、家庭和國家來說有多麼困難。 根據 IDF 糖尿病地圖集(2021 年),10.5% 的成年人(20-79 歲)患有糖尿病,近一半的人根本不知道自己患有糖尿病。 根據 IDF 預測,到 2045 年,八分之一的成年人(即 7.83 億人)將患有糖尿病,增幅為 46%。 2 型糖尿病是由社會經濟、人口、環境和遺傳變量驅動的,影響 90% 以上的糖尿病患者。 在預測期內,隨著糖尿病患者越來越意識到這些泵和疾病管理的好處,市場預計將會增長。
增加產品發布和批准
隨著糖尿病在新興國家變得更加普遍,市場參與者需要專注於技術改進產品的研發,並將新產品推向市場。 此類研發舉措得到了眾多臨床研究的支持,這些研究表明,與接受 MDI 治療的 2 型糖尿病患者相比,接受泵治療的 2 型糖尿病患者的血糖控制持續改善。 因此,預計該市場在未來幾年將會增長。
市場製約因素
胰島素泵通常很昂貴
在預期期間,市場增長預計將受到胰島素泵高成本的限制。 這些現代藥物輸送系統正在徹底顛覆傳統的醫療保健動態,這也正在改變醫療保健領域。 例如,美國糖尿病協會2019年4月進行的一項研究發現,糖尿病患者的胰島素泵治療比MDI治療更昂貴,價格差異約為43.5%。 此外,與這些泵相關的高額自付費用也阻礙了患者使用它們。
產品展望
按產品劃分,市場分為泵和消耗品。 2022年,泵領域佔據市場最大的銷售份額。 該細分市場的擴張是由於發達國家糖尿病患者越來越多地使用泵。 與多個連續血糖監測儀、每日註射和其他技術相比,這些產品具有多種優勢。 據 Tandem 高管稱,隨著該泵在國內和國際市場上獲得關注,預計該泵在 1 型糖尿病患者中的應用將會擴大。
泵類型展望
按泵類型,市場分為貼片泵、系鏈泵和其他泵。 2022年的市場中,系留式將擁有最高的收入份額。 該細分市場的巨大市場規模主要歸功於經典泵的可靠性和廣泛的產品陣容。 繫繩泵因其便攜性和方便放在口袋裡而變得越來越受歡迎。 您還可以使用移動設備輕鬆控制和監測您的血糖水平。 這些優點增加了對繫繩泵的需求。
按適應症劃分的展望
按照糖尿病適應症,市場分為 1 型糖尿病和 2 型糖尿病。 2 型糖尿病細分市場將在 2022 年獲得顯著的市場收入份額。 由於 2 型糖尿病在全球範圍內的患病率不斷上升,預計該疾病在預測期內將逐漸增長。 越來越多的胰島素依賴型 2 型糖尿病患者以及從 MDI 轉向泵和其他替代治療的患者也將推動市場擴張。
分銷渠道前景
按分銷渠道劃分,市場分為零售/網上藥房和醫院藥房。 2022年,零售和在線藥房領域佔據市場最高銷售份額。 該市場由零售和在線藥房領域推動,該領域佔據了市場的很大一部分,因為糖尿病管理設備和解決方案在發達國家和新興國家的零售店和藥店更容易獲得。 互聯網的日益普及也促進了這一利基市場的擴大。
區域展望
按地區劃分,我們對北美、歐洲、亞太地區和拉美地區 (LAMEA) 的市場進行了分析。 2022年,北美地區以最高的收入份額引領市場。 這是由該地區多個主要市場進入者、糖尿病患病率上升以及社會對新給藥技術不斷增長的需求推動的。 由於可支配收入的增加和健康意識的提高,胰島素泵的採用率預計將在預測期內保持該地區的領先地位。
The Global Insulin Pump Market size is expected to reach $9.5 billion by 2030, rising at a market growth of 9.9% CAGR during the forecast period.
Asia-Pacific region widely utilizes Insulin Pumps as a sizable portion of the world's population resides in Asia Pacific, and the region's consumers are changing their eating habits, leading to an increase in the number of diabetics. Hence, Asia Pacific captured $1,090.5 million revenue in the market in 2022. Additionally, it is anticipated that in the near future, rising consumer healthcare spending, increased retail pharmacy penetration, and rising health awareness in the region will fuel the expansion of the market in Asia Pacific.
The major strategies followed by the market participants are Partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, In March, 2023, Diabeloop SA entered into a partnership with Novo Nordisk to integrate its 4penTM with Novo Nordisk's reusable and connected insulin pens. The integration of the two offerings would bring better-automated solutions to diabetic patients. Additionally, In June, 2022, SOOIL Developments Co., Ltd partnered with Diabeloop, to integrate their offerings. The interoperability between the offerings would provide customers with better diabetes management solutions.
Based on the Analysis presented in the KBV Cardinal matrix; F. Hoffmann-La Roche Ltd. is the forerunner in the Market. In January, 2021, F. Hoffmann-La Roche Ltd. entered into a partnership with Montmed Inc. to provide a SiteSmart pen needle system to Canadian customers. The partnership aids Roche in its goal of improving diabetes management. Companies such as Medtronic PLC, Aetna, Inc., Insulet Corporation are some of the key innovators in the Market.
COVID-19 Impact
The COVID-19 outbreak hindered the market expansion for insulin pumps. Delays in diabetes diagnosis and treatment, as well as in patients' purchases of these pumps at this time, were contributing factors. Additionally, during the COVID-19 pandemic, restrictions put in place by several governments resulted in interruptions in the delivery of pumps and supplies. For example, the American Diabetes Association reports that 15% of diabetics who use pumps or CGMs delayed replenishing their supplies during the pandemic. Due to rising disease awareness & diagnosis, CGM and closed-loop pump sales showed a 20% increase in 2021. The revenue margins of the market participants significantly decreased in 2020.
Market Growth Factors
Growing incidence of diabetes globally
Both in developed and emerging nations, diabetes is becoming more common. This is a result of several elements, such as obesity and a sedentary lifestyle. Facts and numbers on diabetes indicate how much of a hardship it is for people, families, and nations worldwide. 10.5% of adults (20-79 years) have diabetes, according to the IDF Diabetes Atlas (2021), and nearly half are completely ignorant that they have the disease. According to IDF predictions, 783 million adults, or one in eight, would have diabetes by 2045, a 46% rise. Type 2 diabetes, caused by socioeconomic, demographic, environmental, and hereditary variables, affects more than 90% of diabetics. During the forecast period, the market is expected to rise due to diabetic patients being more aware of these pumps and the advantages of disease management.
Rising product launches and approvals
The market players are urged to focus on research and development of technologically improved products and introduce new items to the market as the penetration of these pumps among diabetics in emerging nations rises. These R&D initiatives have been supported by numerous clinical studies that demonstrate sustained improvement in glucose control in type 2 diabetic individuals receiving pump therapy as opposed to those receiving MDI therapy. As a result, the market is predicted to grow in the upcoming years.
Market Restraining Factors
Insulin pumps are generally expensive
During the anticipated term, market growth is expected to be constrained by the high cost of insulin pumps. The dynamics of conventional healthcare have been upended by these contemporary drug delivery systems, which have also changed the healthcare sector. For instance, a study conducted by the American Diabetes Association in April 2019 found that insulin pump therapy for diabetic patients is more expensive than MDI therapy, with a price difference of about 43.5%. Also, the greater out-of-pocket costs related to these pumps have discouraged patients from using them.
Product Outlook
On the basis of product, the market is bifurcated into pumps and consumables. In 2022, the pumps segment witnessed the largest revenue share in the market. The segment's expansion results from the diabetic population's rising use of them in industrialized nations. Compared to several continuous glucose monitors, daily injections, and other technologies, these goods provide several advantages. The adoption of pumps among patients with type 1 diabetes is expected to grow as they gain traction in both the domestic and international markets, according to senior Tandem executives.
Pumps Type Outlook
By pumps type, the market is divided into patch, tethered and others. The tethered held the highest revenue share in the market in 2022. The segment's significant market size is primarily attributable to the classic pumps' dependability and the wide range of products available. Due to their portability and convenience, that allow people to carry them in their pockets, tethered insulin pumps have grown in popularity. It may also be easily controlled and used to monitor blood glucose levels via mobile devices. These benefits have led to a rise in the demand for tethered pumps.
Disease Indication Outlook
By diabetes indication, the market is fragmented into Type 1 Diabetes, and Type 2 Diabetes. The Type 2 Diabetes segment garnered a significant revenue share in the market in 2022. Due to the rising prevalence of this condition worldwide, it is also anticipated that the type 2 diabetes segment will grow gradually throughout the course of the projected period. The market's expansion will also be aided by the rising number of type 2 diabetics who are insulin-dependent and by the patients switching from MDIs to pumps and another alternative treatment alternative.
Distribution Channel Outlook
By distribution channel, the market is bifurcated into retail & online pharmacy and hospital pharmacy. In 2022 the retail & online pharmacy segment held the highest revenue share in the market. The retail & online pharmacy segment, which had a sizable portion of the market, led because diabetic management devices &solutions were more readily available in retail & pharmaceutical outlets in developed and developing countries. The growing use of the internet also contributes to the market expansion in this niche.
Regional Outlook
Region wise, the market is analysed across North America, Europe, Asia-Pacific, and LAMEA. In 2022, the North America region led the market by generating the highest revenue share. This is aided by multiple major market participants in the region, higher diabetes prevalence, and rising public demand for novel medication delivery technologies. The population's adoption of insulin pumps has been prompted by rising disposable income and health awareness, and the region is expected to maintain its leadership during the forecast period.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, F. Hoffmann-La Roche Ltd., Tandem Diabetes Care, Inc., Insulet Corporation, Ypsomed AG, Aetna, Inc. (CVS Pharmacy, Inc.), SOOIL Developments Co., Ltd, Diabeloop SA, Jiangsu Delfu Medical Device Co.,Ltd, and APEX Medical Corporation
Recent Strategies Deployed in Insulin Pump Market
Partnerships, Collaborations, and Agreements:
2023-Mar: Diabeloop SA entered into a partnership with Novo Nordisk, a Danish healthcare company, to integrate its 4penTM with Novo Nordisk's reusable and connected insulin pens. The integration of the two offerings would bring better-automated solutions to diabetic patients.
2022-Nov: Ypsomed AG teamed up with CamDiab, a glucose level management solutions provider, to launch an automated insulin dosing system. The collaboration features the integration of Ypsomed's offerings with CamDiab's adaptive hybrid closed-loop app that would allow Ypsomed to better serve its diabetic patients.
2022-Jun: SOOIL Developments Co., Ltd partnered with Diabeloop, a diabetes management solutions provider, to integrate their offerings. The interoperability between the offerings would provide customers with better diabetes management solutions.
2021-Nov: Diabeloop SA announced a partnership with Terumo Corporation, a medical technology company, to develop solutions for Automated Insulin Delivery. The partnership enhances Diabeloop's position in the European market and would provide its customers with better diabetes care solutions.
2021-Jan: F. Hoffmann-La Roche Ltd. entered into a partnership with Montmed Inc., an Insulin delivery specialist based in Canada, to provide a SiteSmart pen needle system to Canadian customers. The partnership aids Roche in its goal of improving diabetes management.
Mergers & Acquisition:
2023-May: Medtronic PLC acquired EOFlow Co. Ltd., an insulin delivery solutions provider. The acquisition strengthens Medtronic's diabetes management portfolio.
2023-Feb: Insulet Corporation took over the automated insulin delivery assets of Automated Glucose Control LLC, an automated insulin delivery solution provider based in the United States. The acquisition would strengthen the company's ability to deliver automated insulin delivery technology.
2023-Feb: Insulet Corporation announced the acquisition of automated insulin delivery assets of Bigfoot Biomedical, an intelligent injection solutions provider. The acquisition enhances Insulet's IP portfolio.
2023-Jan; Tandem Diabetic Care, Inc. completed the acquisition of AMF Medical SA, an Insulin patch pump manufacturer. The acquisition would enhance the diabetes management expertise of the company by adding a well-experienced team.
Trials and Approvals:
2023-Apr: Medtronic PLC announced the approval by U.S. Food and Drug Administration (FDA) for its MiniMed 780G. The MiniMed 780G is an insulin injector system used when the consumer puts low carbs in their meal.
2023-Apr: The US FDA announced the approval for Insulet Corporation's Omnipod GO, an insulin delivery device used for the treatment of type 2 diabetes.
2022-Feb: Tandem Diabetes Care, Inc. received approval from U.S. Food and Drug Administration for its t:slim X2 insulin pump. The t:slim X2 is used to monitor glucose levels in the patient's body. Additionally, the t:slim X2 can be used along with t:connect mobile app.
Product Launches and Product Expansions:
2022-Nov: Medtronic PLC released the Medtronic Extended infusion set. The infusion set has a wear time of 7 days and uses a tubing connector that would be used for insulin stability.
2021-Mar: Roche has announced the launch of the new Accu-Chek Instant system, a new "connected" blood glucose monitoring (BGM) system, which supports and enables Roche's approach of integrated Personalized Diabetes Management (iPDM). iPDM is a holistic, patient-centered therapeutic approach with the ultimate goal of personalizing diabetes management to streamline care and improve clinical outcomes. iPDM aims to strengthen the care process, facilitates communication between patients and their healthcare team, and integrates tools that visualize and analyze data.
Geographical Expansions:
2022-Jun: Insulet Corporation expanded its geographical footprint by opening a new manufacturing facility in Johor Bahru, Malaysia. The new facility would be used for manufacturing the company's Omnipod Insulin Management System.
Market Segments covered in the Report:
By Product
By Disease Indication
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures